Vir Biotechnology, Inc. ($VIR) reported second-quarter 2026 revenue of $238.9 million, far above the year-ago period and also ahead of Wall Street’s $218.6 million estimate. Gross profit matched revenue at $238.9 million, reflecting minimal cost of sales during the quarter.
The company posted operating profit of $73.5 million and net income attributable to common shareholders of $80.1 million. Diluted earnings per share came in at $0.47, topping the $0.34 consensus estimate.
Cash generation was also strong, with operating cash flow of $123.3 million. Vir ended the quarter with $278.7 million in cash and cash equivalents, while total liabilities stood at $232.3 million.
- Revenue: $238.9 million
- Diluted EPS: $0.47
- Operating cash flow: $123.3 million
- Cash and cash equivalents: $278.7 million
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Vir Biotechnology, Inc. Insider Trading Activity
Vir Biotechnology, Inc. insiders have traded $VIR stock on the open market 23 times in the past 6 months. Of those trades, 0 have been purchases and 23 have been sales.
Here’s a breakdown of recent trading of $VIR stock by insiders over the last 6 months:
- VICKI L SATO has made 0 purchases and 6 sales selling 108,377 shares for an estimated $1,043,189.
- BACKER MARIANNE DE (President and CEO) has made 0 purchases and 3 sales selling 106,360 shares for an estimated $946,964.
- VERNEUIL VANINA DE (EVP, General Counsel, Corp Sec) has made 0 purchases and 3 sales selling 21,262 shares for an estimated $197,374.
- BRENT SABATINI (SVP, Chief Accounting Officer) has made 0 purchases and 5 sales selling 12,879 shares for an estimated $113,087.
- MARK EISNER (EVP and Chief Medical Officer) has made 0 purchases and 3 sales selling 5,594 shares for an estimated $49,523.
- JASON O'BYRNE (EVP & Chief Financial Officer) has made 0 purchases and 2 sales selling 3,723 shares for an estimated $31,145.
- JANET NAPOLITANO sold 3,200 shares for an estimated $30,239
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Vir Biotechnology, Inc. Hedge Fund Activity
We have seen 159 institutional investors add shares of Vir Biotechnology, Inc. stock to their portfolio, and 71 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAR1 CAPITAL MANAGEMENT, LLC added 2,744,714 shares (+inf%) to their portfolio in Q1 2026, for an estimated $24,592,637
- ORBIMED ADVISORS LLC removed 2,380,715 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $21,331,206
- SB INVESTMENT ADVISERS (UK) LTD removed 2,168,884 shares (-16.5%) from their portfolio in Q1 2026, for an estimated $19,433,200
- SOLEUS CAPITAL MANAGEMENT, L.P. added 2,002,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $17,937,920
- POINT72 ASSET MANAGEMENT, L.P. added 1,756,516 shares (+897.5%) to their portfolio in Q1 2026, for an estimated $15,738,383
- GOLDMAN SACHS GROUP INC added 1,681,323 shares (+107.2%) to their portfolio in Q1 2026, for an estimated $15,064,654
- BLACKROCK, INC. added 1,668,226 shares (+10.2%) to their portfolio in Q1 2026, for an estimated $14,947,304
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Vir Biotechnology, Inc. Price Targets
Multiple analysts have issued price targets for $VIR recently. We have seen 6 analysts offer price targets for $VIR in the last 6 months, with a median target of $20.5.
Here are some recent targets:
- Michelle Gilson from Morgan Stanley set a target price of $27.0 on 06/11/2026
- Roanna Ruiz from Leerink Partners set a target price of $21.0 on 06/03/2026
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $20.0 on 03/04/2026
- Etzer Darout from Barclays set a target price of $30.0 on 02/25/2026
- Joseph Stringer from Needham set a target price of $18.0 on 02/24/2026
- Cory Kasimov from Evercore ISI Group set a target price of $18.0 on 02/24/2026
